HDL therapy: two kinds of right?

Area of Science:

• Cardiovascular medicine
• Lipid metabolism
• Pharmacology

Background:

• Cardiovascular disease is a leading global health concern, often managed by controlling atherogenic lipids like LDL and triglycerides.
• Increasing high-density lipoprotein (HDL) levels shows promise for improved patient outcomes, despite complex regulatory pathways.
• Current therapeutic strategies targeting HDL have yielded limited success due to the intricate HDL metabolic pathway.

Purpose of the Study:

• To review the evidence supporting and opposing current methods for increasing HDL levels.
• To explore the complexities of HDL metabolism and its therapeutic targeting.
• To investigate potential strategies for correcting adverse effects associated with HDL-raising drugs.

Main Methods:

• Literature review of studies on HDL metabolism and therapeutic interventions.
• Analysis of evidence regarding the efficacy and safety of HDL-raising drugs.
• Exploration of HDL particle heterogeneity and the role of cellular receptors.

Main Results:

• The HDL metabolic pathway is highly complex, hindering successful drug development.
• Controversy exists regarding the most cardio-protective HDL particle and the relevance of mouse models to human HDL receptor function.
• Current approaches to raising HDL have shown limited success and potential adverse effects.

Conclusions:

• Further research is needed to fully understand HDL metabolism and identify effective therapeutic targets.
• Addressing HDL particle heterogeneity and species-specific receptor importance is crucial for developing successful HDL-modulating therapies.
• Strategies to mitigate adverse effects of HDL-raising drugs require further investigation.